• LAST PRICE
    162.3800
  • TODAY'S CHANGE (%)
    Trending Down-4.0000 (-2.4041%)
  • Bid / Lots
    161.3700/ 4
  • Ask / Lots
    162.3200/ 4
  • Open / Previous Close
    163.8700 / 166.3800
  • Day Range
    Low 161.3600
    High 163.9900
  • 52 Week Range
    Low 126.9681
    High 225.2300
  • Volume
    22,459
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 166.38
TimeVolumeBGNE
09:32 ET1746163.87
09:39 ET100163.3
09:43 ET1176163.7
09:45 ET542162.61
09:50 ET322162.69
09:52 ET200162.23
09:54 ET100161.36
09:59 ET1212161.86
10:01 ET2407161.99
10:03 ET345161.925
10:06 ET900161.86
10:08 ET100161.875
10:12 ET400162.26
10:14 ET100162.38
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBGNE
Beigene Ltd
16.8B
-21.5x
---
United StatesBMRN
Biomarin Pharmaceutical Inc
16.1B
78.9x
---
United StatesUTHR
United Therapeutics Corp
12.5B
13.5x
+8.22%
United StatesNBIX
Neurocrine Biosciences Inc
13.5B
37.0x
+62.04%
United StatesALNY
Alnylam Pharmaceuticals Inc
20.1B
-59.1x
---
United StatesMEDP
Medpace Holdings Inc
12.5B
39.5x
+35.10%
As of 2024-06-14

Company Information

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Contact Information

Headquarters
C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
Phone
345-949-4123
Fax
---

Executives

Co-Founder, Executive Chairman of the Board, Chief Executive Officer
John Oyler
President, Chief Operating Officer, General Manager - China
Xiaobin Wu
Co-Founder, Non-Executive Director
Xiaodong Wang
Chief Financial Officer
Julia Wang
Senior Vice President, General Counsel
Chan Lee

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$16.8B
Revenue (TTM)
$2.8B
Shares Outstanding
104.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.61
EPS
$-7.57
Book Value
$36.95
P/E Ratio
-21.5x
Price/Sales (TTM)
6.1
Price/Cash Flow (TTM)
---
Operating Margin
-26.60%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.